Study to Compare the Safety and Efficacy of ALZ-1101 to Latanoprost in Patients With Intraocular Pressure Inadequately Controlled by Latanoprost

NCT01896180 | Completed Phase 2

• 1 other identifier: ALZ-1101-101
• Study Type: interventional
• Target: 63
• Locations: 1 country
• Sites: 1

Brief Summary

This is a pilot, proof of concept study to evaluate the safety and efficacy of ALZ-1101 dosed once daily for 28 days compared to latanoprost 0.005% ophthalmic solution in patients with elevated intraocular pressure not adequately controlled with latanoprost.

Conditions

Primary Open Angle Glaucoma; Ocular Hypertension; Elevated Intraocular Pressure

Keywords

POAG; OHT; OHTN; IOP

Outcome Measures

Primary Outcomes (1)

• Goldmann applanation tonometry

  Between-group comparison of the mean IOP values at the 10 AM time point at Visit 5 (Day 28).

  28 days

Secondary Outcomes (4)

• Goldmann applanation tonometry

  28 days

• Goldmann applanation tonometry

  28 days

• Goldmann applanation tonometry

  28 days

• Safety

  28 days

Study Arms (2)

ALZ-1101

EXPERIMENTAL

ALZ-1101 ophthalmic solution dosed as 1 drop, once daily in the evening via topical ocular adminstration

Drug: ALZ-1101

Latanoprost

ACTIVE COMPARATOR

Latanoprost 0.005% ophthalmic solution dosed as 1 drop, once daily in the evening via topical ocular administration

Drug: Latanoprost

Interventions

ALZ-1101 DRUG

ALZ-1101 Ophthalmic Solution

ALZ-1101

Latanoprost DRUG

Latanoprost 0.005% Ophthalmic Solution

Latanoprost

Eligibility Criteria

• Age: 18 Years+
• Sex: all
• Healthy Volunteers: No
• Age Groups: Adult (18-64), Older Adult (65+)

You may qualify if:

• Age 18 years or older.
• Primary open-angle glaucoma or OH on treatment with latanoprost 0.005% QD.
• At least one eye with IOP \> 18 mm Hg but ≤ 28 mm Hg at all time points (8 AM, 10 AM, and 4 PM) while on latanoprost monotherapy QD at Screening and Baseline (Day 0) visits. Measurements will be taken each visit at 8 AM, 10 AM, and 4 PM (each ± 30 minutes), with AM measurements of IOP at least 2 hours apart. Screening must be at least one week before but within 2 weeks prior to Baseline.
• On latanoprost 0.005% QD for at least 4 weeks prior to randomization.
• Shaffer gonioscopic grade of ≥ 3 (in at least 3 quadrants) in both eyes.
• Stable corrected Snellen visual acuity (VA) better than 20/200 in the study eye.
• Central corneal thickness between 480-620 μm in the study eye.
• Female subjects must be 1-year postmenopausal, surgically sterilized, or women of childbearing potential with a negative urine pregnancy test at Visit 1. Women of childbearing potential must use an acceptable form of contraception throughout the study. Acceptable methods include the use of at least one of the following: intrauterine (intrauterine device), hormonal (oral, injection, patch, implant, ring), barrier with spermicide (condom, diaphragm), or abstinence.
• Provide signed written consent prior to participation in any study-related procedures.

You may not qualify if:

• A mean deviation of \< -20 dB on visual field (VF) assessment.
• Presence of a scotoma within 5°of fixation on VF.
• Aphakia.
• Use of any antiglaucoma medication in addition to latanoprost QD within 2 weeks prior to Visit 1 or during the study period.
• Use of any topical ophthalmic steroid or nonsteroidal anti-inflammatory drug (NSAID) within 2 weeks prior to Visit 1 or during the study period.
• Use of systemic carbonic anhydrase inhibitor within 2 weeks prior to Visit 1 or during the study period.
• Ocular surgery or ocular laser treatment of any kind within 3 months prior to Visit 1 or during the study period.
• Any history of glaucoma surgery (laser or non-laser).
• History of ocular allergy/inflammation and/or severe blepharitis and/or uveitis. Seasonal allergic conjunctivitis is acceptable (avoid enrollment of subjects who may experience seasonal flare-up during the study period). Mild blepharitis/blepharoconjunctivitis, typically associated with prostaglandin usage, is acceptable.
• History of ocular trauma or ocular infection within 3 months of Visit 1.
• History of herpes simplex keratitis.
• Current proliferative diabetic retinopathy or age-related macular degeneration, unless deemed not clinically significant by the Investigator.
• Severe dry eye (eg, clinically relevant superficial punctate keratitis, epithelial erosions of the cornea, and/or use of dry eye medication \[including artificial tears\] with a frequency exceeding 8 applications per day).
• Contact lens wear within one week prior to Visit 1 or during the study period (contact lens wear in an untreated fellow eye is allowed).
• Angle closure or occludable angles (Shaffer gonioscopic grade of \< 3).

Sponsors & Collaborators

• Alleanza Pharmaceuticals, Inc.: lead

Study Sites (1)

Unknown Facility

Morrow, Georgia, United States

Location

MeSH Terms

Conditions

Glaucoma, Open-Angle; Ocular Hypertension

Interventions

Latanoprost

Condition Hierarchy (Ancestors)

Glaucoma; Eye Diseases

Intervention Hierarchy (Ancestors)

Prostaglandins F, Synthetic; Prostaglandins, Synthetic; Prostaglandins; Eicosanoids; Fatty Acids, Unsaturated; Fatty Acids; Lipids; Autacoids; Inflammation Mediators; Biological Factors

Study Design

• Study Type: interventional
• Phase: phase 2
• Allocation: RANDOMIZED
• Masking: SINGLE
• Who Masked: OUTCOMES ASSESSOR
• Purpose: TREATMENT
• Intervention Model: PARALLEL
• Sponsor Type: INDUSTRY
• Responsible Party: SPONSOR

Study Record Dates

• First Submitted: July 8, 2013
• First Posted: July 11, 2013
• Study Start: July 1, 2013
• Primary Completion: January 1, 2014
• Study Completion: January 1, 2014
• Last Updated: September 30, 2014

Record last verified: 2014-09

Locations

US (1)